DOI: 10.1055/s-00000071

Seminars in Neurology

References

Coles AJ, Cohen JA, Arnold DL. , et al.
On behalf of the CARE-MS I Investigators. Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).

Mult Scler 2016;
22 (S3): 75

Download Bibliographical Data

Search in: